Analgesia

Hypophyllanthin
Catalog No: CFN98431

Hypophyllanthin and phyllanthin have antitumour effects against Ehrlich Ascites Carcinoma in mice. Hypophyllanthin can modulate the vascular tension via the endothelium-independent mechanisms, it can directly inhibit P-gp activity and does not interfere with MRP2 activity, it may reversibly inhibit P-gp function. Hypophyllanthin offers a promising means for treatment of chronic muscle pain. Hypophyllanthin also has estrogenic properties against carbofuran induced toxicity in female rats.

Buddlejasaponin IV
Catalog No: CFN98519

Buddlejasaponin IV has analgesic and anti-inflammatory effects, the inhibitions of the expressions of iNOS, COX-2, TNF-alpha, IL-1beta and IL-6 by blocking NF-kappaB activation. Buddlejasaponin IV exerts cytotoxic effects against cancer cells,it can induce cell cycle arrest at G2/M phase and apoptosis in immortalized human oral keratinocytes, it may possess antimetastatic potential by inducing anoikis and upregulating NAG-1 expression. Buddlejasaponin IV can inhibit intrinsic and extrinsic hyperlipidemia and hypercholesterolemia in the rat.

3'-O-Methylorobol
Catalog No: CFN98492

3'-O-Methylorobol exhibits moderate antioxidant activity in the 2,2-diphenyl-1-picrylhydrazyl free radical scavenging assay, it also exerts potential analgesic properties. 3'-O-Methylorobol can increase osteoblast differentiation.

Vitexin
Catalog No: CFN98601

Vitexin, an HIF-1alpha inhibitor, which has anticonvulsant, anti-depressant, anti-glycation, spasmolytic, anti-metastatic, antitumor, anti-inflammatory and antinociceptive activities. Vitexin can be effectively used for the prevention of UV-induced adverse skin reactions such as free radical production and skin cell damage; it non-competitively inhibits Ach but not the Ca(2+) influx.

Benzoylmesaconine
Catalog No: CFN98575

Benzoylmesconine has analgesic activity. Benzoylmesconine may improve the resistance of T6S-mice (or thermally injured mice) to the infection of HSV-1, through the induction of antagonistic CD4+ T cells against burn-associated type-2 T cells.